Previous 10 | Next 10 |
– Late-breaking phase 3 data for KONFIDENT trial on Sunday, February 25, 2024 – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibito...
2024-02-15 12:18:48 ET Summary KalVista Pharmaceutical announces positive phase 3 data for its oral therapy, sebetralstat, for hereditary angioedema. Sebetralstat's rapid onset of symptom relief, oral administration, and favorable safety profile give it a competitive edge in the o...
2024-02-15 06:43:24 ET More on KalVista Pharmaceticals KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade) KalVista: On Demand Oral Treatment For HAE Signifies Differentiated Advancement Two biotech/pharma stocks to watch - ST...
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) today announced the pricing of its underwritten public offering of (i) 7,016,312 shares of its common stock at a price to the public of $15.25 per share and (ii) pre-funded warrants to purchase 3,483,688 shares of common sto...
2024-02-14 16:29:45 ET KalVista Pharmaceuticals ( NASDAQ: KALV ) intends to offer and sell shares of its common stock and pre-funded warrants to purchase shares of common stock in lieu of KalVista common stock to certain investors in an underwritten public offering. In additio...
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) announced today that it intends to offer and sell shares of its common stock and pre-funded warrants to purchase shares of common stock in lieu of KalVista common stock to certain investors in an underwritten public offering...
2024-02-14 14:31:52 ET Summary Sebetralstat has a compelling drug profile for the on-demand treatment of HAE attacks and could become the new standard of care in a billion-dollar market opportunity. KalVista is transitioning to a commercial company following positive Phase 3 data ...
2024-02-14 00:18:03 ET Read the full article on Seeking Alpha For further details see: Two Biotech/pharma stocks to watch - STTK, KALV
2024-02-13 08:18:56 ET DENVER, Colo., Feb. 13, 2024 ( www.247marketnews.com )- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) reported, this morning, positive results from the phase 3 KONFIDENT clinical trial demonstrating statistically and clinically significant efficacy of sebetralstat ...
2024-02-13 07:17:05 ET More on KalVista Pharmaceticals KalVista: On Demand Oral Treatment For HAE Signifies Differentiated Advancement Seeking Alpha’s Quant Rating on KalVista Pharmaceticals Historical earnings data for KalVista Pharmaceticals Financia...
News, Short Squeeze, Breakout and More Instantly...
KalVista Pharmaceuticals Inc. Company Name:
KALV Stock Symbol:
NASDAQ Market:
KalVista Pharmaceuticals Inc. Website:
- Regulatory filings planned for US, EU, UK and Japan to enable multiple 2025 commercial launches – - Development strategy refined for oral Factor XIIa program – - Organizational focus to drive results and set path to positive cash flow – KalVist...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that William C. Fairey has been appointed to the Company’s Board of Directors, ef...
2024-04-12 19:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...